Literature DB >> 16258221

Successful high dose glucocorticoid treatment for subacute neuromyelitis optica with systemic lupus erythematosus.

Noriko Hagiwara1, Kazunori Toyoda, Takeshi Uwatoko, Kotaro Yasumori, Setsuro Ibayashi, Yasushi Okada.   

Abstract

A 54-year-old Japanese woman with a 6-year history of systemic lupus erythematosus (SLE) was admitted to our hospital suffering from acute blindness in her right eye. Her condition recovered after steroid pulse therapy, however, 18 months later she suffered from nuchal pain for 2 weeks after which right hemiparesis with urinary incontinence developed. A spinal magnetic resonance imaging (MRI) revealed cord swelling from C2 to C7. She was diagnosed with neuromyelitis optica (NMO) and intravenous steroid administrations were immediately commenced. Her condition promptly improved. This case was unique because the steroid treatment was quite effective for this case of myelitis, which had passed the acute phase. We supposed that, because most of the lesion was not necrotic or demyelinated, but rather showed edematous change caused by vasculitis based on autoimmune pathogenesis, the symptoms progressed rather gradually and improved promptly in response to glucocorticoid treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258221     DOI: 10.2169/internalmedicine.44.998

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  4 in total

1.  A report of three cases with lupus myelitis.

Authors:  Hiroshi Oiwa; Toru Yamabe; Masanori Kawashima; Yuta Maetani; Dai Agari; Takemori Yamawaki; Eiji Sugiyama
Journal:  Eur J Rheumatol       Date:  2017-06-01

Review 2.  Autoimmune optic neuropathy.

Authors:  James Goodwin
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

Review 3.  Neuromyelitis Optica-AQP4: an update.

Authors:  Emilio Benavente; Sergio Paira
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.686

Review 4.  Neuromyelitis optica pathogenesis and aquaporin 4.

Authors:  David J Graber; Michael Levy; Douglas Kerr; William F Wade
Journal:  J Neuroinflammation       Date:  2008-05-29       Impact factor: 8.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.